IDEXX stock jumps 20.2% after beating earnings and raising guidance, boosting S&P 500 funds.

IDEXX Laboratories surged 20.2% after reporting stronger-than-expected Q3 earnings and raising its full-year revenue and EPS guidance. The veterinary diagnostics company showed growth despite a weak market for vet visits, driven by recurring revenue and new acquisitions. As an S&P 500 component, IDEXX's gain benefits index funds, though its impact on broad funds is small due to its relatively low weighting. Healthcare sector funds holding IDEXX see a more noticeable effect. Investors should watch upcoming product launches and margin trends for future performance clues.

IDEXX Laboratories shares jumped 20.94% on Pluang, reaching USD 666.66 as of Nov 03, 2026 03:02 WIB, slightly above the article's 20.2% rise. The Health Care Select Sector SPDR Fund (XLV), which includes IDEXX, showed little movement with a 0.04% gain at USD 184.91. This highlights IDEXX's strong individual performance compared to its broader sector fund.